Figure 1 | Scientific Reports

Figure 1

From: Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease

Figure 1

ASOA19 (3-9-2-1) efficiently downregulated the level of SNCA mRNA in HEK293 cells. (a) qPCR analysis showing the expression levels of SNCA mRNA in HEK293 cells. A total of 50 AmNA-ASOs were individually transfected into HEK293 cells. ASOA19 significantly reduced levels of hSNCA mRNA. Data are expressed as mean ± SEM (n = 6). **p < 0.01 by Dunnett’s test. (b) Sequences of ASOA19 containing various gapmer motifs. Capital and small letters represent AmNA and DNA, respectively. (c) Assessment of ASOA19 with variable gapmer motifs. qPCR analysis showing the expression levels of SNCA mRNA in HEK293 cells. ASOA19 (3-9-2-1) reduced SNCA mRNA more efficiently than the other modified ASOA19. Data are expressed as mean ± SEM (n = 3).

Back to article page